Why ACA Is A Boon For Health Care, Hospitals: An Interview With Tom Scully
Ex-CMS administrator Thomas Scully, who has played an important role in moving forward some key federal health policy initiatives, including Medicare Part D, is optimistic about the Affordable Care Act’s impact on several sectors of health care, notably hospitals, and biopharma – in contrast to the industry’s general uncertainty and nervousness around implementation.
You may also be interested in...
Health care exchanges for expanding insurance coverage as part of the Affordable Care Act will open in time to meet the law’s January 1 deadline, but their “robustness” and ease of use, at least initially, may be questionable, a panel of experts tells Wall Street.
Most health reform watchers have been tracking state votes on Medicaid expansion as a sort of scorecard on whether Obama Administration is winning or losing in health care reform. Push back from the states is making news now, but for biopharma sponsors, even a glass half full is a positive—and the long-term outlook is even brighter.
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?